AAPG
AAPGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company carries a $1.75B market cap, placing it firmly in the small-cap category. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Market Cap
$1.75B
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
-15.75
EPS (TTM)
$-2.05
EPS (Fwd)
$-1.19
ROE
-154.6%
ROA
-23.0%
Cash
$2.47B
Total Debt
$1.98B
Free CF
-$942.6M
52W Change
-53.6%
Annual Financials
Cash vs Debt
With $2.47B in cash and $1.98B in debt, AAPG maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$942.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -154.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $209.7M (2022) to $574.1M (2025), reflecting a 174% increase over the period.
AAPG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AAPG and its sector.